Disclosure and Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE and TFF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE and TFF are committed to providing learners with high-quality CME.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.
Faculty Disclosures:
The faculty listed below report that they have relevant financial relationships to disclose:
- Anne Peters, MD, serves on advisory boards for Abbott Diabetes Care, Lilly, NovoNordisk, AstraZeneca, Vertex, Medscape, and Zealand. She does research funding for Dexcom, Insulet, and Abbott Diabetes Care. She also reports stock options for Omada Health and Teladoc.
- Archana Sadhu, MD, FACE, serves on the speakers bureau for Sanofi Aventis
- Jay Shubrook, DO, FACOFP, FAAFP, serves on an advisory board for Bayer, NovoNordisk, and Sanofi
The following faculty report that they have no relevant financial relationships to disclose:
- Jane Jeffrie Seley, DNP, MSN, MPH, GNP, CDE, BC-ADM, CDTC, FAADE, FAAN
Disclosure of Unlabeled Use
AACE and TFF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
|